Patent · US Active

Methods of treatment using novel LHRH antagonists having improved solubility properties

US7732412B2 · kind B2 · utility

0Cited by

8References

8Claims

0Family size

Assignee

Zentaris GmbH · DE

Inventors

Michael Bernd · Frankfurt, DE
Bernhard Kutscher · Maintal, DE
Eckhard Gunther · Offenbach, DE
Peter Romeis · Gelnhausen, DE
Thomas Reissmann · Frankfurt, DE
Thomas Beckers · Konstanz, DE

Key dates

Filing date	Jul 24, 2006
Grant date	Jun 8, 2010
Priority date	—
Expiry date	Jul 24, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K7/23
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. The invention also relates methods for treating a hormone-dependent tumor or a non-malignant indication that is treatable by LH-RH suppression, the method comprising administering to a patient in need of the treatment a therapeutically effective amount of a compound of the invention. Hormone-dependent cancers that can be treated with the methods of the invention include prostate cancer, breast cancer, ovarian cancer, endometrial cancer, and pancreatic cancer. Non-malignant indications which can be treated by the methods of the invention include benign prostate hyperplasia (BPH), endometriosis, acne, polycystic ovarian disease, dysmenorrhea, precocious puberty, and uterine fibroids and other leiomyomas.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.